Us sucralfate market

U.S. Sucralfate Market by Formulation (Tablet and Liquid Suspension), by Indication (Gastric Ulcers, Duodenal Ulcers, Gastro Esophageal Reflux Disease (GERD), and Others Indications), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by State (Illinois, Texas, New York, California, and Others) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Request Free Sample

Aug 2019
CMI2975
129 Pages
Excel & Pdf
Pharmaceutical

Summary

U.S. Sucralfate Market – Market Insights

The U.S. sucralfate market size was valued at US$ 296.2 million in 2017, and is expected to exhibit a CAGR of 3.1% over the forecast period (2018–2026).

Figure 1. U.S. Sucralfate Market Value (US$ Mn), by Distribution Channel, 2018

Market Value (US$ Mn),

Source: Coherent Market Insights Analysis (2019)

Increasing prevalence of gastrointestinal disorders and H. pylori-associated infections is expected to propel the market growth

Rising incidence of gastric ulcers caused due to use of nonsteroidal anti-Inflammatory drugs (NSAID) and H. pylori infection is expected to drive the U.S. sucralfate market. According to the study by Deccan College of Medical Sciences, 2016, an estimated 95% of duodenal and 70% of gastric ulcers are caused due to Helicobacter pylori. Furthermore, the same study also stated that around 14-25% of gastric and duodenal ulcers are associated with NSAID use.

Rising prevalence of peptic ulcers is expected to bolster the market growth. According to the data published by ScienceDirect Journal in 2016, duodenal ulcers are more common type of peptic ulcers and its prevalence was around 6% to 12% in the U.S.

Figure 2. U.S. Sucralfate Market Share (%), by Distribution Channel, 2018 and 2026

Source: Coherent Market Insights Analysis (2019)

Increasing collaboration and acquisition strategies adopted by market players is expected to bolster the market growth

The U.S. sucralfate market is expected to witness significant growth, owing to increasing inorganic growth strategies such as collaboration and acquisitions by market players. For instance, in 2014, Aptalis Pharma Inc., a specialty pharmaceutical company and manufacturer of Carafate, was acquired by Forest Laboratories, Inc., a fully integrated, specialty pharmaceutical company. Forest agreed to acquire Aptalis from TPG, the global private investment firm, for US$ 2.9 billion in cash.

Increasing applications and uses of sucralfate in the U.S. is expected to drive the market growth. According to the American Broncho Esophagological Association report, in April 2018, use of sucralfate along with honey aids in treatment of esophageal injury in infants and children. Esophageal injury in infants and children are associated with consumption of Button Batteries (BB), small disc-shaped batteries commonly found in toys.

Moreover, increasing prevalence of gastro-esophageal reflux disease (GERD) and Helicobacter pylori infection is expected to bolster the U.S. sucralfate market over the forecast period. For instance, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the prevalence of GERD was reported in the range from 15% to 30% in the U.S. in 2014. Similarly, according to the data published in American Gastroenterological Association (AGA) Journal in 2017, the prevalence of Helicobacter pylori positive infection is 35.6% among the population in the U.S.

Key Players

Major players operating in the U.S. sucralfate market include Teva Pharmaceutical Industries Ltd., Allergan plc, Vertice Pharma LLC, and Pharmaceutical Associates Inc.

Table of Content

Table of Contents

*Browse 22 market data tables and 17 figures on "Sucralfate Market - U.S. forecast to 2026”.

N/A

- Frequently Asked Questions -

What are the growth estimates for the U.S. sucralfate market till 2026?

The U.S. sucralfate market is estimated to surpass US$ 388.2 Million by 2026.

Which are the prominent U.S. sucralfate market players?

Major players operating in the U.S. sucralfate market include Teva Pharmaceutical Industries Ltd., Allergan plc, Vertice Pharma LLC, and Pharmaceutical Associates Inc.

What factors are influencing the adoption ofsucralfate?

Sucralfate is the generic form of the brand-name drug, Carafate. It is a prescription medicine used to treat ulcers of the upper gastrointestinal tract, peptic ulcer disease, and to prevent reoccurrence of ulcers.Rising incidence of gastrointestinal disorders and H. pylori-associated infections is one of the factors that is influencing adoption of sucralfate in the U.S.

What are the key factors driving growth of the U.S. sucralfate market?

Increasing prevalence of gastrointestinal disorders and H. pylori-associated infections is one of the major factors that is expected to propel growth of the market over the forecast period.

What is the compound annual growth rate (CAGR) of the U.S. sucralfate market for next 8 years?

The U.S. sucralfate market is estimated to exhibit a CAGR of 3.1% over the forecast period.

Which segment based on formulation, accounted for the highest demand in the U.S. sucralfate market?

Among formulation, tablet segment held a dominant position in the U.S. sucralfate market in 2018.